Table 1 Summary table showing compound name, binding affinity, and functional activity

From: Identification of nanomolar adenosine A2A receptor ligands using reinforcement learning and structure-based drug design

 

A2A

A2B

Compound

pKi (± SD)

pIC50 (± SD)

pEC50 (± SD)

Emax (%± SD)

pEC50

pIC50

1

4.8 (±0.3)

Inactive

Inactive

ND

Inactive

Inactive

2

5.0 (±0.8)

Inactive

Inactive

ND

Inactive

Inactive

3

5.9 (±0.3)

Inactive

Inactive

ND

Inactive

Inactive

4 (Isomer 1)

6.4 (±0.0)

5.3 (±0.4)

Inactive

ND

Inactive

Inactive

4 (Isomer 2)

6.2 (±0.1)

6.5 (±0.4)

Inactive

ND

Inactive

Inactive

5

5.7 (±0.1)

Inactive

7.3 (±0.1)

65 (±6.8)

Inactive

Inactive

6

5.9 (±0.0)

Inactive

Inactive

ND

Inactive

Inactive

7

7.3 (±0.1)

7.6 (±0.1)

7.7 (±0.2)

−289 (±17.1)

Inactive

Inactive

8

4.4 (±0.1)

Inactive

5.9 (±0.2)

−179 (±3.8)

Inactive

Inactive

9

7.5 (±0.1)

7.7 (±0.1)

6.5 (±0.1)

−181 (±5.9)

Inactive

Inactive

  1. [3H]-ZM241385 radioligand competition binding assays for the compounds synthesised were carried out in BacMam transfected A2A cells. Effects of the compounds synthesised on the levels of cAMP measured after overexpression of the wild-type A2A, either alone (pEC50) or in the presence of an EC80 of NECA (pIC50). ND refers to not determined. Values correspond to the mean and standard deviation (SD) with n = 2 technical replicates for binding assays confirmed by n = 3 technical replicates on independent orthogonal agonist and antagonist functional assays.